Low-Dose Naltrexone Year-1 Outcomes: What Real Users Actually Report

Low-dose naltrexone (LDN) is the opioid antagonist naltrexone, the same molecule sold at 50 mg under the brand ReVia for opioid and alcohol use disorder, compounded down to doses between roughly 0.5 mg and 4.5 mg and taken nightly off-label. It is not a different drug and it is not FDA-approved at these doses. Everything below concerns that low-dose, compounded, off-label use, not the approved 50 mg product.

The useful question for a reader deciding whether to start LDN is not "does it work," which patient communities answer with confidence, but "how much of what those communities report has actually been tested in a controlled trial, and how much is pattern-matching on a slow, subjective symptom." The honest answer is mixed: a handful of small controlled trials support real effects in specific conditions, mainly fibromyalgia and Crohn's disease, while most of what circulates about autoimmune disease, long COVID, and long-term dose stability comes from patient self-report that has not been tested against placebo.

The core, quotable answer: low-dose naltrexone has been evaluated in small, mostly short-duration randomized trials showing reduced pain in fibromyalgia and improved response rates in Crohn's disease compared with placebo, but these trials generally ran 8 to 16 weeks with only limited open-label follow-up, so the abundant patient reports of stable benefit at 12 months are not yet backed by large, long-duration controlled data. No LDN formulation is FDA-approved for any indication, and the drug is absolutely contraindicated in anyone using opioid medications because it can precipitate withdrawal at any dose.

What is established, what is plausible, and what is not established

Established:

• Naltrexone 50 mg is FDA-approved for opioid and alcohol use disorder. LDN doses below 5 mg are off-label and require compounding, since no manufacturer makes a tablet in that range.
• Small randomized or crossover trials have reported pain reduction with LDN compared with placebo in fibromyalgia, and improved short-term response and remission rates compared with placebo in a pediatric Crohn's disease pilot trial. These trials involved small numbers of participants (on the order of tens, not hundreds) over 8 to 12 weeks.
• LDN precipitates opioid withdrawal in anyone currently using opioid analgesics or opioid agonist therapy, and this contraindication is absolute regardless of the LDN dose used.
• Common early side effects reported in both trials and patient accounts are vivid dreams and disrupted sleep, typically in the first several weeks, sometimes improved by shifting the dose to morning.

Plausible but unproven:

• A dual mechanism combining transient opioid-receptor rebound with toll-like receptor 4 (TLR4) antagonism on microglia, proposed to explain effects across pain and autoimmune conditions. This mechanism has support from laboratory and mechanistic research summarized in review articles, but a mechanism being plausible does not establish that a given clinical claim built on it is true.
• That most patients who benefit settle into a stable dose (commonly cited as 3 mg or 4.5 mg) without escalation or tolerance over a full year. This is a consistent theme in patient self-report but has not been confirmed in a large prospective cohort followed for 12 months.
• Benefit in Hashimoto's thyroiditis, chronic fatigue syndrome/ME, and other autoimmune conditions. Evidence here is limited to case reports, small case series, and patient community reports rather than randomized trials.

Not established:

• Any specific year-1 discontinuation rate, side-effect percentage, or "percent improvement" figure that can be cited with confidence at the population level. The source studies for several of these commonly repeated statistics could not be verified against the primary literature for this draft, and precise numbers should not be treated as settled until an editor confirms the underlying paper.
• That LDN meaningfully changes the disease course of multiple sclerosis. A small trial reported quality-of-life improvements without evidence of change on MRI measures, which is a different claim from disease modification.
• Any guideline recommendation naming LDN as first-line or standard-of-care therapy for any condition. As of early 2025, mainstream rheumatology, gastroenterology, and pain-medicine guidance treats it as an emerging or investigational option rather than a recommended one; readers should confirm current guideline language with their own society sources, since guidance can change.

Why compounding is necessary, and what that means for consistency

The FDA has approved naltrexone at 50 mg (oral) and as a 380 mg extended-release injectable for opioid and alcohol use disorder (FDA label). Neither approved product exists at LDN doses, so patients obtain 1.5 mg to 4.5 mg capsules or liquid from compounding pharmacies that reformulate the approved tablet. Naltrexone is not currently listed as a bulk substance approved for 503A/503B compounding nomination, and oversight of individual compounding pharmacies varies by state (FDA compounding policy overview). Pharmacies accredited through voluntary non-sterile compounding standards are generally considered more consistent, but accreditation is not mandatory, and patients splitting or diluting standard 50 mg tablets at home risk uneven dosing because the tablets are not designed for sub-milligram division.

This matters for interpreting year-1 outcomes: a patient report of "LDN stopped working" or "LDN never worked" may reflect an actual lack of drug effect, or it may reflect a compounding inconsistency that changed the delivered dose. Trials use pharmacy-controlled formulations; real-world reports do not, and that gap is rarely acknowledged in patient discussions.

What the trial evidence shows, by condition

Fibromyalgia has the strongest controlled signal for LDN. Crossover trials led by the same research group at Stanford reported reduced pain scores with LDN compared with placebo over roughly 8 to 12 week periods, with effects becoming more apparent after the first several weeks of treatment. Sample sizes were small (on the order of 30 participants), and an open-label extension followed a subset of those participants for about a year without new safety signals reported, but this was not itself a placebo-controlled year-long trial. Readers should treat the magnitude of pain reduction as a real but preliminary finding, not a settled number, until an editor verifies the exact effect size against the original paper.

Crohn's disease has a notable pediatric pilot trial reporting substantially higher response and remission rates with LDN compared with placebo over 12 weeks, with better endoscopic improvement scores in the treatment group. This was a single small trial. Gastroenterology professional societies have not incorporated LDN into standard Crohn's disease treatment guidance, and it should be understood as an adjunct or investigational option discussed with a treating gastroenterologist, not a substitute for guideline-based Crohn's therapy.

Multiple sclerosis data are more limited. A small phase II trial reported improved mental-health-related quality-of-life scores with LDN compared with placebo but did not find a difference in MRI lesion counts, which argues against LDN acting as a disease-modifying therapy for MS even if it affected how patients felt day to day.

Autoimmune conditions more broadly (Hashimoto's, lupus, psoriasis) rest on case reports and small series. A systematic review of LDN in autoimmune disease found the evidence base thin and called for randomized trials; that conclusion, not a specific effect estimate, is the safe takeaway for this population today.

What patients report at 12 months, and why that is a different kind of evidence

Patient communities (Reddit forums, pharmacy and telehealth review sites) describe a consistent narrative: several weeks of no noticeable effect, followed by a gradual reduction in pain interference and improved sleep once early insomnia resolves, with most long-term users describing stability rather than escalation by month 12. This pattern is worth taking seriously as a hypothesis-generating signal. It is not, on its own, evidence that LDN caused the improvement, because these reports have no placebo comparison, no blinding, and substantial reporting bias (people who feel better post more, and people who stopped without benefit may simply leave the community rather than post a negative update).

The most commonly cited reasons for stopping before month 12 in patient discussions are unresolved sleep disruption, no perceived benefit by around 12 to 16 weeks, and cost or pharmacy access problems. These are plausible and consistent with the known side-effect profile, but a precise year-1 discontinuation percentage for the general LDN population has not been confirmed here against a primary source and should not be quoted as an established figure.

Who should not use LDN, and when to seek care instead of waiting it out

LDN is absolutely contraindicated in anyone taking opioid analgesics or opioid agonist therapy (including methadone or buprenorphine), because receptor blockade at any dose can trigger acute withdrawal. The naltrexone label carries this warning at the approved 50 mg dose, and it applies with equal force at low doses since the mechanism of blockade is the same.

Relative cautions include active liver disease or significantly elevated liver enzymes (naltrexone carries a hepatotoxicity warning at higher doses; the risk at 1.5 to 4.5 mg is plausibly lower but has not been specifically studied in patients with liver impairment), pregnancy (naltrexone has not been adequately studied in human pregnancy), and concurrent use of immune-modulating medications, where an interaction is theoretical rather than demonstrated.

Anyone on LDN who develops jaundice, dark urine, right upper quadrant abdominal pain, or unexplained fatigue with these features should seek prompt medical evaluation rather than waiting for a scheduled follow-up. Anyone who develops symptoms of opioid withdrawal after starting LDN while on an opioid should seek urgent care.

Sourcing, prescribing, and cost considerations

Naltrexone at any dose requires a prescription in the United States; there is no over-the-counter version. Telehealth platforms in most states can prescribe LDN following a clinical evaluation, and the off-label rationale should be documented by the prescriber. Because LDN is off-label, most commercial insurance plans do not cover it, and standard prescription discount programs generally do not apply to compounded medications, so patients typically pay cash-pay compounding pharmacy prices that vary by pharmacy and region. Readers should get a current quote from their own pharmacy rather than relying on a fixed price figure, since compounding costs shift over time and by location.

Evidence-review framework: what to conclude, and what decision it supports

Use this framework to sort any specific claim about LDN, whether it comes from a forum post, a clinician, or a marketing page, into a category that tells you how much weight it can bear.

The pattern across every row: the further a claim sits from a controlled trial, the more it describes what is possible rather than what is proven. A reasonable year-1 decision rule is to set an explicit review point (commonly discussed as week 12-16 for a first read, and month 6 and month 12 for durability) and compare your own symptom tracking against your own baseline, not against an average from a small trial or an anecdote from a forum.

What the FDA and guideline bodies actually say

The FDA has not approved any LDN formulation for any indication; naltrexone is approved only at 50 mg oral and as the 380 mg extended-release injectable for addiction indications (FDA label). Prescribers extrapolate from that safety record to sub-5 mg doses, an extrapolation that is pharmacologically reasonable given the shared molecule but has not been separately validated in large, long-duration studies at LDN doses. Mainstream fibromyalgia, gastroenterology, and multiple sclerosis guideline bodies have generally described LDN as an emerging or investigational option rather than a first-line, guideline-recommended therapy as of early 2025; because guideline language changes, confirm current wording directly with the relevant professional society before relying on it for a specific claim.